Acta materia medica最新文献

{"title":"Network pharmacology-guided discovery of avicularin from Euphorbia humifusa Willd. targeting IL-17 signaling in psoriasis","authors":"Qianqian Zhou, Zhe Wang, Yuanxiang Wang, Jiawei Guan, Linyun He, Jiwen Yang, Yaping Chi, Li Zhao, Bo Zhang, Kewu Zeng, Hua Zhang, Bo Han","doi":"10.15212/amm-2025-0058","DOIUrl":"https://doi.org/10.15212/amm-2025-0058","url":null,"abstract":"Despite therapeutic advances, long-term psoriasis management remains challenged by cost, immunogenicity, and administration barriers. Although the anti-inflammatory properties of avicularin (AL) are recognized, its direct targeting of IL-17RA and its therapeutic efficacy in psoriasis remain unreported. Here, we established the efficacy of Euphorbia humifusa Willd. (EH) in a psoriasis mouse model, then used an integrated strategy combining network pharmacology, RNA-seq, and surface plasmon resonance-mass spectrometry (SPR-MS) to assess its pharmacodynamic material basis. This systematic approach identified the IL-17 pathway as the primary mechanism, and IL-6, CXCL10, and IL-17RA as key targets. On the basis of these key targets, SPR-MS screened seven candidate compounds from EH, among which AL was confirmed as a key IL-17RA-targeting bioactive compound. Subsequent validation demonstrated that AL dose-dependently ameliorated psoriatic lesions and downregulated key IL-17 pathway effectors, including IL-17RA, IL-6, and CXCL10 ( p < 0.05). Direct binding between AL and IL-17RA was subsequently confirmed through bio-layer interferometry, SPR-MS re-screening, and molecular docking. Our findings not only establish AL as a promising oral IL-17RA-targeted agent but also delineate a robust strategy that may aid in the systematic discovery of active natural compounds.","PeriodicalId":72055,"journal":{"name":"Acta materia medica","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147878190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PROTAC technology for prostate cancer treatment.","authors":"Zhen Wang, Dingpeng Zhang, Hiroyuki Inuzuka, Wenyi Wei","doi":"10.15212/amm-2024-0075","DOIUrl":"10.15212/amm-2024-0075","url":null,"abstract":"<p><p>Prostate cancer (PrCa) is the most prevalent urogenital cancer in men, marked by uncontrolled cellular growth that leads to abnormal enlargement of the prostate gland. The metastatic spread of PrCa is the primary cause of mortality, causing cancer cells disseminate to distant sites, such as bones, the pelvis, and other organs. Key contributors to PrCa progression include genetic mutations, elevated androgen receptor (AR) expression, gene amplification, and the rise of AR splice variants. Although androgen deprivation therapy (ADT) remains the mainstay for early-stage PrCa treatment, its efficacy is rather temporary, as many cases advance to castration-resistant PrCa (CRPC), presenting a significant therapeutic hurdle. This review explores key biomarkers for PrCa and the latest therapeutic strategies for CRPC, with a particular focus on the innovative Proteolysis-targeting chimera (PROTAC) technology. This approach offers a novel means of degrading target proteins, and we discuss how PROTACs hold potential as effective strategies to combat resistance mechanisms in CRPC.</p>","PeriodicalId":72055,"journal":{"name":"Acta materia medica","volume":"4 1","pages":"99-121"},"PeriodicalIF":0.0,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12360713/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144884402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Euphorbia neriifolia L. extract attenuates heart failure by modulating the Nrf2/ROS/HIF-1α signaling pathway","authors":"Taotao Lu, Manjiong Wang, Yunyuan Huang, Donglei Shi, Xiao Li, Jiaqi Liu, Jian Li, Bei Jiang, Baoli Li, Yixiang Xu","doi":"10.15212/amm-2025-0056","DOIUrl":"https://doi.org/10.15212/amm-2025-0056","url":null,"abstract":"Heart failure (HF) remains a major global health challenge with limited therapeutic options, thus prompting the search for novel cardioprotective agents among traditional Chinese medicines. In this study, screening of 828 herbal extracts in an oxygen glucose deprivation injury H9c2 cardiomyocyte model led to the identification of Euphorbia neriifolia L. extract (JM04) as a promising candidate. JM04 significantly increased cell viability while decreasing lactate dehydrogenase release and reactive oxygen species (ROS) accumulation in both H9c2 and primary cardiomyocytes. In vivo , JM04 ameliorated cardiac function and attenuated myocardial fibrosis in isoproterenol-induced HF mice, as evidenced by echocardiography and histological analysis. Network pharmacology and mechanistic studies revealed that JM04 modulated the Nrf2/ROS/HIF-1α axis by exerting free radical scavenging activity, activating the Nrf2 antioxidant pathway, restoring mTOR phosphorylation, and enhancing HIF-1α expression, thereby protecting against cardiomyocyte apoptosis. Furthermore, UPLC-MS/MS identified six active components consistent with network pharmacology predictions, thus highlighting its multicomponent and multitarget nature. Collectively, these findings demonstrated that JM04 exerts potent cardioprotective effects through integrated antioxidant and signaling modulation, and support its further development as a candidate botanical drug for HF intervention.","PeriodicalId":72055,"journal":{"name":"Acta materia medica","volume":"4 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147330840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MiR-128-3p mediates MRP2 internalization in estrogen-induced cholestasis through targeting PDZK1","authors":"Yue Zu, Qianyan Gao, Yisheng He, Qiao Deng, Guodong Li, Xiping Li, Tianze Shang, Xinwei Cheng, Chenglong Zhu, Jianqiao Wang, Dong Liu, Chengliang Zhang","doi":"10.15212/amm-2024-0053","DOIUrl":"https://doi.org/10.15212/amm-2024-0053","url":null,"abstract":"Estrogens have been reported to cause dysfunction in biliary transport systems, thereby inducing cholestasis. Multidrug resistance-associated protein 2 (MRP2) is a transporter responsible for independent bile flow. Emerging evidence indicates that PDZ domain containing 1 (PDZK1) regulates localization of MRP2; however, PDZK1’s role and regulatory machinery in MRP2-mediated estrogen-induced cholestasis (EIC) remain unclear. Herein, in a mouse model of EIC, we observed downregulated PDZK1 expression in the liver and enhanced intracellular domain MRP2 internalization. Notably, expression of miR-128-3p, a potential biomarker of estrogen-related cholestasis discovered by our group, was significantly elevated. We demonstrated that miR-128-3p targeted the 3’-untranslated region of PDZK1 in EIC and consequently promoted MRP2 internalization. Accordingly, miR-128-3p suppression upregulated PDZK1, thereby suppressing MRP2 internalization and significantly attenuating cholestatic liver disease. Furthermore, we observed MRP2 internalization and PDZK1 downregulation, as well as excessive miR-128-3p, in clinical samples from patients with cholestatic liver injury. Overall, our findings illustrate that miR-128-3p inhibits PDZK1 expression, thereby inhibiting the membrane localization of MRP2 in EIC. Enhancing or restoring PDZK1 expression might therefore have therapeutic potential for cholestatic liver injury.","PeriodicalId":72055,"journal":{"name":"Acta materia medica","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147901498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Caryota maxima leaf extract extends Caenorhabditis elegans lifespan by inducing mono-unsaturated fatty acid accumulation via DAF-2 signaling","authors":"Zhifan Mao, Haiyan Jiang, Lingyuan Bao, Yuzhu Han, Manjiong Wang, Xiaokang Li, Conglong Xia, Jian Li, Bo Han, Bei Jiang, Zelan Hu","doi":"10.15212/amm-2025-0008","DOIUrl":"https://doi.org/10.15212/amm-2025-0008","url":null,"abstract":"Geroprotectors that delay aging have substantial potential for preventing and mitigating age-related diseases. Natural products derived from traditional herbal medicines are promising candidates for geroprotector discovery, because of their multi-target mechanisms and preventive health benefits. Through screening of 836 Chinese herbal medicine extracts, we identified that the leaf extract of Caryota maxima ( JM13001 ) significantly extended lifespan and healthspan in Caenorhabditis elegans . JM13001 increased total lipid content and upregulated mono-unsaturated fatty acids (MUFAs), which are known to contribute to longevity. JM13001 exerted its effects through DAF-2 signaling, thereby promoting lipid accumulation and extending lifespan in nematodes. Notably, the lifespan-extending effects of JM13001 were abolished after the loss of key enzymes responsible for converting saturated fatty acids to MUFAs or after oleic acid supplementation; therefore, its geroprotective effects are dependent on MUFAs. Chemical analysis revealed that JM13001 contains flavonoids such as rutin, isoquercitrin, and kaempferol-3-O-rutinoside, among which rutin alone was sufficient to reproduce the anti-aging and lipid accumulation promotion effects of JM13001 through DAF-2 signaling. This study identifies a novel geroprotective herbal extract and its active ingredient, thereby providing insights into the anti-aging mechanisms of natural geroprotectors via MUFA metabolism regulation.","PeriodicalId":72055,"journal":{"name":"Acta materia medica","volume":"4 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.scienceopen.com/document_file/2d94f0dc-5632-4382-ad6f-7f8a0c44855f/ScienceOpen/amm20250008.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147333201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Moracin M derivative targeting PDE4 for the treatment of psoriasis","authors":"Liru Chen, Deyan Wu, Sen Wang, Lingyu Wu, Youyou Chen, Baoli Li, Hai‐Bin Luo, Jian Li, Wenwen Liu","doi":"10.15212/amm-2024-0086","DOIUrl":"https://doi.org/10.15212/amm-2024-0086","url":null,"abstract":"Phosphodiesterase-4 (PDE4), a member of the phosphodiesterase superfamily, has highly important roles in cyclic nucleotide signaling pathways and a variety of skin disorders. Blocking PDE4 activity with PDE4 inhibitors increases intracellular cAMP levels and effectively relieves the skin inflammatory phenotype of psoriasis. However, traditional PDE4 inhibitors may cause adverse effects such as gastrointestinal reactions. Natural products typically exhibit safety profiles and structural novelty, which are particularly advantageous for drug discovery. LW, a derivative of the natural product Moracin M, was found to have favorable PDE4 inhibitory activity (PDE4 IC 50 = 54 nM). Examination of LW in psoriasis treatment demonstrated good anti-inflammatory effects in cellular models. In an imiquimod-induced mouse model, LW treatment markedly improved psoriatic symptoms, as evidenced by increased PASI scores and ameliorated skin pathology. Moreover, LW significantly downregulated Inflammatory factors in the serum and alleviated spleen damage. Therefore, LW has substantial therapeutic potential, through effectively decreasing inflammatory factor levels and ameliorating psoriatic skin phenotypes. Our findings support LW as a potential candidate compound for developing new psoriasis treatments.","PeriodicalId":72055,"journal":{"name":"Acta materia medica","volume":"4 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.scienceopen.com/document_file/8266623b-c1c7-438e-badf-02eab19bd7b8/ScienceOpen/amm20240086.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147331354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deciphering the regulatory programs of RNA binding proteins in rheumatoid arthritis through single-cell transcriptome analysis","authors":"Hongbin Luo, Qunya Zheng, Yi Zhou, Weipeng Lai, Nanwen Zhang, Peng Chen","doi":"10.15212/amm-2024-0034","DOIUrl":"https://doi.org/10.15212/amm-2024-0034","url":null,"abstract":"Single-cell RNA sequencing (scRNA-seq) data from published datasets were obtained to investigate the expression and dysregulation of RNA-binding proteins (RBPs), which are critical for alternative mRNA splicing and translational control in rheumatoid arthritis (RA). How RBP regulation differs between RA and osteoarthritis (OA) was examined using RBP for single-cell sub-clustering. Quantitative polymerase chain reactions (PCRs) were performed to confirm differentially expressed RBPs in RA fibroblast-like synoviocytes (FLSs) and OA-FLSs, as well as in mice with collagen-induced arthritis (CIA) and control mice. Additionally, bulk RNA-seq data were collected and RBP-alternative splicing event (ASE) co-expression analyses were performed to reveal the potential regulatory role of RA-related RBPs on ASEs. Significant variations in relative proportions of cell subtypes were demonstrations between RA and OA with downregulated RBPs outnumbering upregulated RBPs in each cell type and showing high specificity for particular subsets. One hundred five upregulated and 133 downregulated RBPs were identified in fibroblasts. Y-Box binding protein 3 (YBX3) and splicing factor 3b subunit 6 (SF3B6) were confirmed to be upregulated in RA-FLS and CIA mice, while eukaryotic translation initiation factor 4A1 (EIF4A1) and U2 small nuclear RNA auxiliary factor 1 (U2AF1) were downregulated in RA-FLS. The RA group displayed stronger cell type interactions compared to the OA group with enhanced signaling pathways, such as fibronectin 1-cluster of differentiation 44 (FN1-CD44) and C-X-C motif chemokine ligand 12-C-X-C motif chemokine receptor 4 (CXCL12-CXCR4). Furthermore, three upregulated genes (spectrin repeat containing nuclear envelope protein 2 [SYNE2], S100 calcium binding protein A9 [S100A9], and interferon induced protein with tetratricopeptide repeats 3 [IFIT3]) and four downregulated genes (ribonuclease 1 [RNASE1], granulin [GRN], FN1, and sorbin and SH3 domain containing 2 [SORBS2]) were co-expressed in RA-associated RBPs and ASEs. These findings suggest that dysregulation of RBPs may contribute to the development of RA and provide potential targets for therapeutic interventions.","PeriodicalId":72055,"journal":{"name":"Acta materia medica","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.scienceopen.com/document_file/85999e81-df7b-42bf-891b-5329a055ec7e/ScienceOpen/amm20240034.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147880132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Berberine inhibits phagocytosis through the TLR4-PI3K-CDC42 pathway","authors":"Jing Chang, Cheng‐Peng Sun, Miaomiao Wang, Wu Li, Yaxue Jia, Juan Zhang, Feng Qiu","doi":"10.15212/amm-2024-0074","DOIUrl":"https://doi.org/10.15212/amm-2024-0074","url":null,"abstract":"Phagocytosis is a fundamental mechanism used by the body to resist pathogens and restore physiological homeostasis. Herein, to identify small molecules with anti-inflammatory properties via phagocytosis inhibition, we constructed a library of natural products and evaluated their ability to modulate phagocytosis in RAW264.7 macrophages. Berberine (BBR) is the major constituent of traditional Chinese medicine Coptidis Rhizoma that is recorded in Chinese Pharmacopoeia with the effect of clearing heat-toxin, and is used in the therapeutic management of various inflammatory diseases. BBR was found to inhibit phagocytosis and significantly alleviate inflammation via suppressing interleukin-1α (IL-1α), interleukin-1β (IL-1β), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α (TNF-α), according to real-time quantitative polymerase chain reaction (RT-qPCR) analyses, and phosphorylated-p65 (p-p65), iNOS, and cyclooxygenase-2 (COX-2), according to western blot analyses. BBR inhibited the expression of F-actin, a key protein in phagosome formation. Notably, BBR exerted its phagocytosis effects through targeting phosphoinositide 3-kinase (PI3K), thereby activating the small GTPase-Cdc42 (CDC42), Wiskott-Aldrich syndrome protein (WASP), and actin-related protein 2/3 complex subunit 2 (Arp2/3). BBR attenuated LPS-mediated inflammation through promoting macrophage phagocytosis. We determined that BBR targets the toll-like receptor 4 (TLR4)-PI3K-CDC42 pathway, thereby inhibiting the nuclear factor-kappa B (NF-κB) pathway, and consequently regulating phagocytosis and the inflammatory response. Our findings suggest that BBR might serve as a candidate for the development of phagocytic inhibitors.","PeriodicalId":72055,"journal":{"name":"Acta materia medica","volume":"4 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.scienceopen.com/document_file/4542c2bc-e773-4e5d-96de-e46ba5857fac/ScienceOpen/amm20240074.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147914989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Discovery of vina-ginsenoside R18 as a novel dual-target inhibitor of dengue virus envelope protein and RNA-dependent RNA polymerase","authors":"Xuemei He, Yuanru Zheng, Lifang Zou, Jingtao Yu, Bing Chen, Zhuolin Guo, Gefei Peng, Zibin Lu, Wei Zhao, Jianping Zuo, Fen Ouyang, Linzhong Yu, Junshan Liu","doi":"10.15212/amm-2024-0094","DOIUrl":"https://doi.org/10.15212/amm-2024-0094","url":null,"abstract":"Dengue virus (DENV) poses a serious health threat globally for which specific antivirals are not available. Envelope (E) protein and RNA-dependent RNA polymerase (RdRp) from DENV represent the most critical targets for the development of antivirals that inhibit viral adsorption for entry and genome replication, respectively; no dual inhibitors targeting E/RdRp have been reported to date. Vina-ginsenoside R18 (R18), a triterpenoid saponin isolated from Panax notoginseng , was shown to target E protein domain III to inhibit binding of E protein to integrin beta3, thus preventing viral adsorption to the host surface receptor. R18 selectively targets RdRp protein and induces a conformational change, leading to a decrease in enzyme activity. Consequently, R18 represses DENV infection by acting at viral binding, entry, and replication stages, and attenuates the pathologic symptoms of DENV-infected ICR suckling and AG129 mice. These results showed R18 to be a novel dual E/RdRp inhibitor that can serve a potential agent against DENV infection.","PeriodicalId":72055,"journal":{"name":"Acta materia medica","volume":"4 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.scienceopen.com/document_file/dde71acf-d1bd-4ccd-90d9-9ee1790386f1/ScienceOpen/amm20240094.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147908870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Discovery of wedelolactone from Eclipta Prostrata (L.) Linn. as a natural PDE4 inhibitor with potent anti-psoriasis effects","authors":"Lingyu Wu, Yingying Wu, Shengchao Yang, Soo Chang Jin, Qing Zhang, Zhongbin Cheng, Chaohui Wu, Yiming Hao, Ling Sun, Wénwén Liú, Donglei Shi, Jianhong Li, Yi-You Huang, Baoli Li, Hai‐Bin Luo","doi":"10.15212/amm-2025-0017","DOIUrl":"https://doi.org/10.15212/amm-2025-0017","url":null,"abstract":"Psoriasis is a chronic inflammatory disorder for which phosphodiesterase-4 (PDE4) inhibitors have emerged as promising therapeutic agents due to an ability to regulate inflammatory signaling pathways. In this study 1200 methanolic extracts from Chinese medicinal plants were screened and Eclipta prostrata (L.) Linn. ( E. prostrata ) was shown to have potent PDE4 inhibitory activity. Bioassay-guided fractionation further demonstrated that the ethyl acetate (EA) fraction exhibited the highest inhibitory activity, leading to the isolation of wedelolactone (WDL) as the principal bioactive compound (IC 50 = 2.8 μM). Molecular dynamics simulations revealed that WDL forms stable interactions with PDE4D through hydrogen bonding and hydrophobic contacts. E. prostrata -EA and WDL significantly suppressed pro-inflammatory cytokines in keratinocytes in vitro . Topical application of WDL demonstrated superior anti-psoriatic efficacy compared to calcipotriol in vivo , as evidenced by reduced Psoriasis Area and Severity Index scores, normalized epidermal thickness, and improved inflammatory cytokine profiles. WDL exhibited favorable metabolic stability in liver microsomes and demonstrated a good safety profile in subacute toxicity assessments with no systemic toxicity. These findings established WDL as a potent and safe topical PDE4 inhibitor, highlighting the potential of WDL as a novel therapeutic candidate for psoriasis and warranting further clinical development.","PeriodicalId":72055,"journal":{"name":"Acta materia medica","volume":"4 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.scienceopen.com/document_file/4b111caa-1fb6-4ffe-9bb9-949bbf7913e2/ScienceOpen/amm20250017.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147331986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}